Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug.
Despite the widespread hype surrounding new and powerful obesity medicines, the drugs are still out of reach for many Americans who could benefit.
One reason is that under current laws, Medicare is barred from covering obesity drugs. But under legislation backed by Novo Nordisk, Eli Lilly, Boehringer Ingelheim and many other organizations, a group of lawmakers aims to change that.
Boehringer Ingelheim, Organon and Samsung Bioepis together, Sandoz, Fresenius Kabi, Celltrion USA, Coherus and Biocon Biologics have released biosimilars of AbbVie's Humira.
After teasing a small data slice in May, Boehringer is now sharing more on its Zealand Pharma-partnered obesity prospect, with new data showing nearly 19% weight loss in a phase 2 trial.
Sanofi (SASY.PA) said on Tuesday that the International Chamber of Commerce rejected rival drugmaker Boehringer Ingelheim's (BI) claims to be indemnified by Sanofi in cancer lawsuits linked to heartburn drug Zantac in the United States.
Today, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes. These approvals provide a new class of medicines taken by mouth to treat pediatric type 2 diabetes. Metformin, the only other oral therapy available for the treatment of children with type 2 diabetes, was first approved for pediatric use in 2000.
diopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). ILDs are characterised by damage to the lung parenchyma (the functional part of the lung that includes the alveolar tissue, bronchioles, bronchi, blood vessels, and interstitium) that occurs as a consequence of aberrant inflammation and fibrosis, thickening, and scarring of the connective tissue. The IPF market is underserved with just two licensed pharmaceutical treatments that are available globally, Roche’s Esbriet/Pirespa (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), which were both approved by the FDA in 2014. Esbriet, a dual anti-fibrotic and anti-inflammatory agent, was launched in Europe in 2012 and in Japan in 2008. Ofev—a small molecule tyrosine kinase inhibitor—gained approvals in only Europe and Japan, in 2015. These two approved therapies merely slow the progression of fibrosis but do not reverse it.
Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda, wagering up to $325 million to get its hands on a preclinical HER2 tyrosine kinase inhibitor (TKI).
Denmark's Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up a potential contestant in the booming obesity drug market.
Boehringer Ingelheim is mining Ginkgo Bioworks’ bioactive molecules in a deal that could add up to $406 million for the cell programming and biosecurity company.
On Monday, Ginkgo announced BI will leverage its metagenomic sequence database to accelerate the development of novel therapeutics, particularly in diseases considered undruggable with high unmet patient needs. Ginkgo’s metagenomic database now comprises over three terabases of sequence data and more than two billion proprietary protein sequences from a variety of microbes, according to the company.